MOXO-Mobile Phase-1 (877041)

  https://cordis.europa.eu/project/id/877041

  Horizon 2020 (2014-2020)

  MOXO-Mobile: the first Attention Deficit Hyperactive Disorder (ADHD) screening mobile application, using Eye Tracking and Continuous Performance Test components to give the first evidence of attention

  SME instrument (EIC-SMEInst-2018-2020)

  mobile phones  ·  unemployment

  2019-08-01 Start Date (YY-MM-DD)

  2020-01-31 End Date (YY-MM-DD)

  € 71,429 Total Cost

  Description

Undiagnosed ADHD leads to learning and social difficulties, school drop-out, unemployment, criminality, and even premature death. Early diagnosis can dramatically improve the quality of life of at least 26 million individuals in the EU, prevent incarceration and recidivism, and save lives. MOXO-Mobile is the first ADHD screening mobile application, combining a Continuous Performance Test (CPT) and Eye Tracking (ET) to give an accurate and simple evaluation of the evidence of attentional difficulties. Using this application, every smartphone user could assess his/her attention level and profile and receive further guidance, in case of need, for further diagnosis. The application will be downloaded for free with pay-per-use strategy as the user will purchase tests as he wishes for himself and his family. MOXO-Mobile will create a new market (ADHD screening), with max market potential of €2.8B, and a projected ROI of 6.1 in 3 years for MOXO-Mobile. SMEi Phase 1 will enable Neurotech-Solutions to conduct a wide feasibility study, establish an elaborated business plan, risk assessment, and a sustainability estimation of the product.

  Complicit Organisations

1 Israeli organisation participates in MOXO-Mobile Phase-1.